Glioblastoma del adultoFase 1NCT04573140Artículos
ARNm tumoral total autólogo
Vacunas de partículas lipídicas de ARN (ARN-LP) para gliomas pediátricos de alto grado (GAGp) y glioblastoma (GBM) del adulto recién diagnosticados
CED crónica de TPT para glioma maligno recurrente
Lo que dice el vídeo
Some brain tumors announce themselves fast. Others take their time. An IDH-mutant glioma is the patient one.
It begins with a typo. IDH is an enzyme in the cell's energy cycle, and in more than seven out of ten lower-grade gliomas, one letter of its gene is wrong. The altered enzyme makes a chemical the body has no use for, and that chemical jams the machinery a cell uses to read its own genes. The tumor that follows grows slowly. It tends to arrive in people in their thirties. And after surgery, radiation and chemotherapy, it comes back. Nearly always, and often more aggressive than before.
When it does come back, there is no standard treatment.
Here is the frustrating part. Drugs that kill these cells in a dish already exist. Topotecan is one. Given by vein, it failed completely in recurrent glioblastoma: in one study, none of twenty-eight patients responded. The drug was not the problem. Getting it to the tumor was.
The brain protects itself. Blood vessels in the brain are sealed shut with tight junctions, and pumps in their walls push foreign molecules back out. It is a good wall, and it cannot tell a poison from a treatment. Raise the dose in the bloodstream enough to force the wall and you poison the rest of the body first.
So what if you skipped the bloodstream?
That is convection-enhanced delivery. A surgeon places a fine catheter into the tumor and the brain around it, and a pump pushes the drug in under gentle pressure. Not diffusion, which fades within millimeters, but bulk flow, which carries a drug centimeters through tissue. Add a contrast agent to the mix and an MRI scan will show you exactly where the drug went.
One more detail shapes the whole design. Topotecan only kills a cell that is actively copying its DNA, and at any moment only a few tumor cells are. A short infusion misses the rest. But the early versions of this ran a tube out through the scalp to a pump at the bedside, and after about four days the risk of infection ends the treatment.
The fix was to put the pump inside the body. A programmable pump, the kind already implanted to deliver pain medicine to the spine, sits under the skin of the chest, is refilled through a needle, and can run as long as it is needed.
In twenty twenty-two, a team at Columbia published the first five patients treated this way. Four infusions of forty-eight hours each, over about a month, with patients at home in between. No severe side effects were blamed on the drug. When the treated tissue was examined afterwards, the share of dividing tumor cells had fallen from roughly four percent to one and a half, and the drug was found as far as six centimeters from the catheter. All five patients eventually died of their disease, and the authors were careful to say that five patients cannot prove benefit.
That study treated a different subtype. This trial brings the method to IDH-mutant tumors for the first time. Six adults whose glioma has returned, at Columbia University in New York, led by Jeffrey Bruce, who has spent a career on this problem. Two operations, four infusions, and one question first. Is it safe?
Everything in this film comes from the published record, and it is not medical advice.
Fuentes de este vídeo
Yan H. N Engl J Med, 2009
IDH is an enzyme in the cell's energy cycle; one wrong letter in more than seven out of ten lower-grade gliomas; Grows slowly; tends to arrive in people in their thirties
Han S. Br J Cancer, 2020
The altered enzyme makes a chemical the body has no use for that jams how a cell reads its genes; Comes back nearly always, often more aggressive
Grows slowly; tends to arrive in people in their thirties; Comes back nearly always, often more aggressive; Topotecan by vein failed: none of twenty-eight patients responded; Raise the intravenous dose and you poison the body first (+3 more lines)
No standard treatment when it returns
Friedman HS. Cancer, 1999
Topotecan by vein failed: none of twenty-eight patients responded
Bhowmik A. Biomed Res Int, 2015
The brain's vessels are sealed with tight junctions and pumps push drugs back out
Shen J. Cancer Res, 2009
The brain's vessels are sealed with tight junctions and pumps push drugs back out
Bobo RH. Proc Natl Acad Sci U S A, 1994
Convection-enhanced delivery: gentle pressure, bulk flow, centimeters not millimeters
Spinazzi EF. Lancet Oncol, 2022
A contrast agent shows on MRI where the drug went; Topotecan only kills cells actively copying DNA, so a short infusion misses the rest; Early versions ran a tube through the scalp and had to stop after about four days; Five patients; four 48-hour infusions over about a month; at home in between (+5 more lines)
Bruce JN. Neurosurgery, 2011
Early versions ran a tube through the scalp and had to stop after about four days
Sonabend AM. Neuro Oncol, 2011
An implanted programmable pump, like those used for spinal pain medicine, refilled through a needle
El fármaco
El topotecán (TPT) es un fármaco de quimioterapia inhibidor de la topoisomerasa. Esta intervención se distingue por su administración mediante un catéter externalizado y una bomba de microinfusión externa (administración potenciada por convección)
Los gliomas malignos están entre los tumores humanos más perniciosos. Son localmente invasivos y recurren de forma universal, a menudo a menos de dos centímetros de la cavidad de resección original.
Aunque numerosos fármacos de quimioterapia muestran una actividad antitumoral significativa en estudios preclínicos, su eficacia en ensayos clínicos ha sido pobre; la administración sistémica no logra niveles terapéuticos del fármaco en las células tumorales por diversos factores, incluida la limitada permeabilidad de la barrera hematoencefálica y la toxicidad sistémica.
El estudio
El objetivo principal de este estudio es establecer la seguridad de la administración crónica potenciada por convección (CED) del fármaco de quimioterapia topotecán en pacientes con glioma maligno recurrente con mutación de la isocitrato deshidrogenasa (IDH-mut). El objetivo secundario es estudiar la distribución del fármaco y evaluar la respuesta tumoral a la CED continua prolongada de topotecán.
La administración potenciada por convección es un método novedoso que permite administrar un fármaco directamente en el cerebro. En la CED se coloca una bomba de fármaco bajo la piel del tórax o el abdomen. La bomba se conecta a un catéter que se tuneliza bajo la piel hasta el cerebro. La punta del catéter infunde el topotecán directamente sobre el tumor cerebral.
Requisitos
Criterios de inclusión tal como figuran en el registro, recortados. La lista completa, con las exclusiones, está en el registro actualizado.
Para ti, o para alguien a quien quieres
Un diagnóstico complejo trae preguntas nuevas cada semana, dentro de un ensayo y fuera de él. Triangle reúne todo tu expediente médico, lo lee contigo en lenguaje claro y te ayuda, a ti y a tu familia, a decidir qué preguntar después.
Después, $9 al mes. Cancela cuando quieras.
Solicitados a tus hospitales y clínicas a través de las redes nacionales. Añade estudios de imagen, patología y cualquier documento en papel.
Informes explicados a medida que llegan, con valores de laboratorio que puedes seguir antes del tratamiento, durante un ensayo y después.
Pregunta sobre tu propio expediente y llega con preguntas para tu oncólogo o el equipo del ensayo.
Comparte un mismo perfil con la familia que te ayuda y con tus médicos.
Los miembros también reciben un análisis profundo de sus historiales y de cualquier dato de secuenciación, incluidos los ensayos clínicos que podrían encajar, revisado por un médico colegiado antes de recibirlo.
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.